Harrow Inc stock gains as analysts see strong revenue growth ahead

Published on 09/03/2026 at 07:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harrow Inc stock has moved higher while analysts project robust revenue growth for the coming quarters, putting the ophthalmic drug specialist back on the radar of growth-oriented investors.

HROW, US4158581094, Illustration mit AI erstellt.

Harrow Inc stock (ISIN US4158581094) has attracted fresh attention after a recent analysis highlighted strong expected revenue growth for the ophthalmic drug maker, with consensus pointing to a sharp acceleration in the second half of 2026 as of September 2, 2026.

Analysts project double-digit revenue growth

According to an overview of research expectations published on September 2, 2026, analysts forecast that Harrow Inc could generate about USD 99 million in revenue in the third quarter of 2026 and roughly USD 137 million in the fourth quarter of 2026, implying year-over-year increases of about 38 percent and 53 percent respectively in those periods.

These projected figures suggest that Harrow’s annualized revenue run rate could move well above USD 400 million if the company delivers on expectations, which would represent a significant scale-up compared with its historical revenue base in prior fiscal years.

Stock performance and valuation context

A same-day valuation snapshot dated September 2, 2026 shows Harrow Inc shares trading around USD 39.05, within a 52-week range of USD 28.54 to USD 54.85, placing the current level in the middle of the observed trading band.

In that snapshot, the analytical fair value estimate for Harrow Inc stood at approximately USD 42.84 per share versus the market price of USD 39.05, indicating an assessed undervaluation on the order of 8.8 percent based on that methodology.

The combination of an intermediate position within the 52-week range and a modest discount to a calculated fair value suggests that, in the eyes of some valuation models, Harrow stock retains upside potential if the forecast revenue trajectory materializes as expected.

Go deeper

Background and more details on Harrow Inc

For more context on Harrow Inc and additional figures beyond this snapshot, you can find further news and regulatory releases in the dedicated ISIN overview.

More on this stock at ad-hoc-news.de Investor Relations

Ophthalmic products as the growth driver

Harrow Inc focuses on branded ophthalmic pharmaceuticals, including sterile intraocular and topical eye treatments used primarily by eye surgeons and ophthalmologists in the United States.

The company’s product portfolio and pipeline target indications such as cataract surgery support, glaucoma, dry eye and other eye care needs, providing a specialized revenue base that benefits from procedure volumes and adoption of newer formulations.

Harrow Inc stock in the market

As of September 2, 2026, Harrow Inc stock is listed on NASDAQ in USD, with the USD 39.05 share price mentioned above serving as a recent market reference point within its 52-week band of USD 28.54 to USD 54.85.